Where we invest

Building on our accelerator partnerships and surgeon network, ASPS Ventures now deploys direct capital into breakthrough medtech, diagnostics, robotics, and regenerative technologies shaping the next decade of reconstructive and aesthetic surgery. In collaboration with leading venture capital and strategic partners, we identify, validate, and guide companies — driving innovation through strategic funding, clinical insight, and expert mentorship.

Portfolio

Strategic Investments

Targeted capital. Surgeon-vetted. Independently sourced.

2025 MTI COHORT

MEDCu is a biotech company that provides wound dressing products that are impregnated with copper oxide microparticles.

Entirety Biomedical develops and manufactures absorbable metal implants with optimized absorption profiles.

2025 MTI COHORT

BRIJ Medical, a medical device maker introduces a new age of post-surgical and trauma incision care with proven technologies.

2025 MTI COHORT

InSoma Bio integrates biology and materials science to solve problems in tissue engineering and regenerative medicine.

2025 MTI COHORT

Regenyx Medical is redefining minimally invasive soft-tissue restoration with Lipogenyx™, a first-in-class, matrix-enhanced fat-grafting platform.

2025 MTI COHORT

Previous Cohorts (2022-2024)

Developer of medical devices designed to improve the lives of patients by minimizing risks associated with medical injections.

Avance Innovations is spearheading the development of the game-changing, patented microsurgical device, ORASIS.

ALUMNI

ALUMNI

Fasciotens helps with the open abdomen - increase the odds, reduce the risks.

ALUMNI

Lattice Medical offers a 3D printed bioabsorbable medical device for breast reconstruction.

ALUMNI

ReConstruct Bio is an innovative venture from Harvard’s Wyss Institute, redefining the fields of medical reconstruction and aesthetics.

ALUMNI

4D EMR is a cloud-based practice management and electronic medical record system built specifically for plastic surgery and medical spa practices.

ALUMNI

Cellulora is developing a novel cellulose-based material for soft tissue repair.

ALUMNI

Fingy3D offers 3D-printed, body-powered finger prosthetics for amputations, which are customized, affordable, and designed to help users regain function.

ALUMNI

Fesarius Therapeutics is a regenerative medicine company developing tissue-engineered solutions for wound healing, including its dermal regeneration platform, DermiSphere™.

MTI x ASPS Plastic Surgery Accelerated Track Cohorts

Current 2025 Cohort

These companies represent the current ASPS x MedTech Innovator Accelerator cohort. ASPS Ventures holds an equity stake in each.

These companies participated in the ASPS x MedTech Innovator Accelerator. ASPS provided mentorship, clinical access, and surgeon network support. ASPS Ventures does not hold equity in these companies.

ImmersiveTouch empowers clinicians with greater precision and consistency of care by accessing new insights from scans.

ALUMNI

Newrotex develops innovative silk-based medical
solutions for the nervous system.

ALUMNI

ALUMNI

SUTUREGARD Medical is a company that develops devices to help with surgical wound closure, particularly for high-tension wounds and those prone to dehiscence.

Limax Biosciences is developing a strong and flexible hydrogel adhesive for wounds inside and outside the body.

ALUMNI

Ad Vital is an AI-powered, all-in-one software platform designed for aesthetic medical practices to simplify daily operations

ALUMNI

MTI Innovation Pipeline

Screening at Scale. Selecting the Best. Delivering Impact.

125+

Companies Screened Annually

5

Companies Selected Annually

Backed by ASPS clinical validation, mentorship and measurable outcomes.

150+

Patents Issued

100+

Peer-Reviewed Publications

23+

Products Launched

18

Cohort Companies

$160 M+

Total Capital Raised

50+

Animal Studies

2

Exits/Acquisitions

29+

Human Studies

$337,500+

MTI Competition Funding